Categories: NewsPharmaceutical

Avalyn to Participate in Multiple Upcoming Investor Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases, today announced that management will participate in the following upcoming investor conferences in August.

Barclays Private Biotech Symposium
Format:     1×1 Meetings
Date:    Wednesday, August 7, 2024
Location:   Virtual
Participants:    Lyn Baranowski, CEO; Douglas Carlson, CFO, CBO
     
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Format:    Company Presentation
Date:   Wednesday, August 14, 2024
Time:   2:30 – 2:50 p.m. ET
Location:   InterContinental Boston, Boston, MA
Participants:   Lyn Baranowski, CEO; Melissa Rhodes, COO
     

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com and follow us on LinkedIn.

Contacts:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

Staff

Recent Posts

Novel Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

New Studies Highlight Machine Learning as Potential Early Risk Detection Strategy CHICAGO, June 20, 2025…

8 hours ago

Artificial Intelligence (A.I.) in Life Science: New Survey of 408 Researchers Reveals Split Sentiment, Surging Adoption, and Rising Trust Barriers

ARLINGTON, Va., June 20, 2025 /PRNewswire/ -- New survey data from 408 global scientists and researchers…

14 hours ago

Salem Dentist (Smiles Of Salem) Stands with Veterans in National Push for Better Healthcare Protections

This Fourth of July, Dr. Harbpinder Shevchenko, DMD of Smiles of Salem is going beyond…

14 hours ago

American Textile Company’s Centennial Gala Marks 100 Years of Success!

Pittsburgh Event Celebrates Employees, Partners and a Commitment to Growth DUQUESNE, Pa., June 20, 2025…

14 hours ago

Nihar Gala Launches CareIQ, a Pioneering Remote Patient Monitoring Company, and Releases Inspiring New Book “The Strength to Endure”

SEAFORD, Del., June 20, 2025 /PRNewswire/ -- Acclaimed physician, entrepreneur, and visionary healthcare leader Nihar Gala…

14 hours ago